Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

282 trials

NCT07012980
Recruiting
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Phase 2 · China · 1 site
Registry update: 16 Oct 2026
NCT06977711
Recruiting
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
Phase 1 · United States · 2 sites
Registry update: 29 Sept 2026
2023-505834-84-00
Recruiting
A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated with Lenalidomide and Rituximab
Phase 2/3 · France · 12 sites
Registry update: 22 Oct 2025
NCT06672705
Recruiting
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Phase 1 · United States · 2 sites
Registry update: 24 Sept 2026
NCT07044050
Recruiting
A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1 · France · 1 site
Registry update: 29 Jun 2025
NCT06703892
Recruiting
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Phase 1 · Taiwan · 1 site
Registry update: 12 Jun 2026
NCT07258563
Recruiting
The TASTY-steering Study
Not applicable · Netherlands · 11 sites
Registry update: 15 Jul 2026
NCT06533579
Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 · United States · 11 sites
Registry update: 26 Oct 2026
NCT06846463
Recruiting
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Phase 2 · United States · 1 site
Registry update: 23 Jan 2026
NCT07489989
Recruiting
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Phase 2 · China · 1 site
Registry update: 24 Mar 2026
NCT06793410
Recruiting
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Phase 2 · Sweden · 5 sites
Registry update: 5 Jun 2025
NCT07070648
Recruiting
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
Not applicable · China · 1 site
Registry update: 17 Jul 2025
NCT07001540
Recruiting
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
Phase 2 · China · 1 site
Registry update: 19 Jun 2025
NCT07078500
Recruiting
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Phase 2 · China · 1 site
Registry update: 19 Aug 2025
NCT06588205
Recruiting
Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
Not applicable · Italy · 20 sites
Registry update: 29 Dec 2025
NCT07057765
Recruiting
Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Not applicable · Egypt · 1 site
Registry update: 10 Jul 2025
NCT06768905
Recruiting
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Phase 1/2 · United States · 1 site
Registry update: 8 May 2026
NCT06829771
Recruiting
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Phase 1/2 · China · 25 sites
Registry update: 30 Jan 2026
NCT06890884
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Phase 2 · Belgium, Germany, United Kingdom, Ireland, Israel, Italy, Japan, Poland, United States · 154 sites
Registry update: 3 Nov 2026
NCT06536049
Recruiting
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 1/2 · United States · 3 sites
Registry update: 25 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.